Novel coronavirus 2019 (SARS-CoV2) pandemic has particularly affected Italy, with a profound impact on the therapeutic strategy for complex disorder such as psoriasis, whose extensive skin damage might expose to an increased infective risk compared to the general population. Psoriasis treatment relies on immunosuppression, and although most experts agree that the benefit-to risk-ratio is in favor of maintaining selective biologic therapies, and small molecules such as apremilast, they recommend dismission if severe COVID-19 symptoms occur.

COVID-19 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care management

Mugheddu C.
Primo
Membro del Collaboration Group
;
Pizzatti L.
Secondo
Membro del Collaboration Group
;
Atzori L.
Penultimo
Writing – Review & Editing
;
Rongioletti F.
Ultimo
Supervision
2020-01-01

Abstract

Novel coronavirus 2019 (SARS-CoV2) pandemic has particularly affected Italy, with a profound impact on the therapeutic strategy for complex disorder such as psoriasis, whose extensive skin damage might expose to an increased infective risk compared to the general population. Psoriasis treatment relies on immunosuppression, and although most experts agree that the benefit-to risk-ratio is in favor of maintaining selective biologic therapies, and small molecules such as apremilast, they recommend dismission if severe COVID-19 symptoms occur.
2020
Apremilast; Coronavirus pandemic; COVID-19; Psoriasis
File in questo prodotto:
File Dimensione Formato  
apremilast covid oligodendroglioma.pdf

Solo gestori archivio

Tipologia: versione editoriale (VoR)
Dimensione 552.3 kB
Formato Adobe PDF
552.3 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11584/295111
Citazioni
  • ???jsp.display-item.citation.pmc??? 24
  • Scopus 29
  • ???jsp.display-item.citation.isi??? 27
social impact